Jon Saxe Net Worth

The estimated Net Worth of Jon S Saxe is at least $3.03 Million dollars as of 19 March 2021. Mr. Saxe owns over 2,500 units of Vistagen Therapeutics stock worth over $18,116 and over the last 21 years he sold VTGN stock worth over $2,853,240. In addition, he makes $153,847 as Independent Chairman of the Board at Vistagen Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Saxe VTGN stock SEC Form 4 insiders trading

Jon has made over 41 trades of the Vistagen Therapeutics stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 2,500 units of VTGN stock worth $3,750 on 19 March 2021.

The largest trade he's ever made was exercising 120,000 units of Vistagen Therapeutics stock on 9 April 2008 worth over $510,000. On average, Jon trades about 9,268 units every 67 days since 2003. As of 19 March 2021 he still owns at least 5,751 units of Vistagen Therapeutics stock.

You can see the complete history of Mr. Saxe stock trades at the bottom of the page.

Jon Saxe biography

Jon S. Saxe J.D. serves as Independent Chairman of the Board of the Company. He has served as Chairman of our Board since 2000, first as Chairman of the Board of Directors of VistaGen California, then as Chairman of our Board after completion of the Merger. He also serves as the Chairman of our Audit Committee. Mr. Saxe is the retired President and was a director of PDL BioPharma from 1989 to 2008. From 1989 to 1993, he was President, Chief Executive Officer and a director of Synergen, Inc. (acquired by Amgen). Mr. Saxe served as Vice President, Licensing & Corporate Development for Hoffmann-Roche from 1984 through 1989, and Head of Patent Law for Hoffmann-Roche from 1978 through 1989. Mr. Saxe currently is a director of Durect Corporation (NASDAQ: DRRX), and six private life science companies, Achelios, Arbor Vita Corporation, Aether, Inc., Arcuo Medical, LLC, Cancer Prevention Pharmaceuticals, Inc., Trellis Bioscience, Inc. and Epalex Corporation. Mr. Saxe has also served as a director of other biotechnology and pharmaceutical companies, including ID Biomedical (acquired by GlaxoSmithKline), Sciele Pharmaceuticals, Inc. (acquired by Shionogi), Amalyte (acquired by Kemin Industries), Cell Pathways (acquired by OSI Pharmaceuticals), Lumos Pharma, Inc. (merged with New Link Genetics) and other companies, both public and private. Mr. Saxe has a B.S.Ch.E. from Carnegie-Mellon University, a J.D. degree from George Washington University and an LL.M. degree from New York University.

What is the salary of Jon Saxe?

As the Independent Chairman of the Board of Vistagen Therapeutics, the total compensation of Jon Saxe at Vistagen Therapeutics is $153,847. There are 9 executives at Vistagen Therapeutics getting paid more, with Shawn Singh having the highest compensation of $933,667.

How old is Jon Saxe?

Jon Saxe is 84, he's been the Independent Chairman of the Board of Vistagen Therapeutics since 2011. There are no older and 15 younger executives at Vistagen Therapeutics.

What's Jon Saxe's mailing address?

Jon's mailing address filed with the SEC is C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Vistagen Therapeutics

Over the last 8 years, insiders at Vistagen Therapeutics have traded over $147,300 worth of Vistagen Therapeutics stock and bought 1,944,506 units worth $18,208,989 . The most active insiders traders include Healthcare Capital Partners..., Capital Lp Commodore, and Jon S Saxe. On average, Vistagen Therapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $378,372. The most recent stock trade was executed by Capital Lp Commodore on 7 August 2023, trading 775,756 units of VTGN stock currently worth $17,958,751.

What does Vistagen Therapeutics do?

we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.

Complete history of Mr. Saxe stock trades at Durect Corp, Incyte, PDL Biopharma Inc, and Vistagen Therapeutics

Vistagen Therapeutics executives and stock owners

Vistagen Therapeutics executives and other stock owners filed with the SEC include:

• Shawn Singh,
  Chief Executive Officer, Director
• Shawn K. Singh J.D.,
  CEO & Director
• H. Ralph Snodgrass,
  President, Founder, Chief Scientific Officer, Director
• Jerrold Dotson,
  Chief Financial Officer, Vice President, Secretary
• Mark Smith,
  Chief Medical Officer
• Dr. Mark A. Smith M.D., Ph.D.,
  Chief Medical Officer
• Dr. H. Ralph Snodgrass Ph.D.,
  Founder, Pres & Chief Scientific Officer
• Jerrold D. Dotson CPA, CPA,
  CFO, VP & Sec.
• Mark McPartland,
  Vice President - Corporate Development
• Jon Saxe,
  Independent Chairman of the Board
• Ann Michelle Cunningham M.B.A.,
  Chief Commercial Officer & Director
• Valter Pinto,
  Investor Relations
• Brian Underdown,
  Independent Director
• Jerry Gin,
  Independent Director
• Ann Cunningham,
  Independent Director
• Dr. Mark J. Ginski,
  Sr. VP and Head of Chemistry, Manufacturing & Controls
• Mark Adrian McPartland,
  VP of Corp. Devel.
• Healthcare Capital Partners...,
  
• Margaret M Fitz Patrick,
  
• Joanne Curley,
  
• Mary L. Rotunno,
  
• Mark J Ginski,
  SENIOR VP, HEAD OF CMC
• Joshua S. Prince,
  Chief Operating Officer
• Cynthia Lynn Anderson,
  CHIEF FINANCIAL OFFICER
• Capital Lp Commodore,
  10% owner
• Reid G. Adler,
  CHF CORP DEVEL OFF, GEN COUNS